Skip to main content

Table 2 Demographic and other baseline characteristics

From: Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

  Arm A Arm B Arm C Arm D Overall
  (N=60) (N=64) (N=58) (N=59) (N=241)
Age (years)      
Median (Range) 58.5 (37-76) 57.5 (31-74) 56 (38-77) 55 (33-76) 57 (31-77)
  N (%) N (%) N (%) N (%) N (%)
Ethnic Origin, N (%) Caucasian 58 (96.6) 63 (98.4) 58 (100) 59 (100) 238 (98.8)
African 1 (1.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Asian 1 (1.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4)
Othera 0 (0.0) 1 (1.6) 0 (0.0) 0 (0.0) 1 (0.4)
Menopausal status, N (%) pre 19 (31.7) 17 (26.6) 16 (27.6) 21 (35.6) 73 (30.3)
post 41 (68.3) 47 (73.4) 42 (72.4) 38 (64.4) 168 (69.7)
Karnofsky Performance Status, N (%) Point      
Able to care for self 70 0 (0.0) 0 (0.0) 2 (3.5) 2 (3.4) 4 (1.66)
Normal activity but requiring effort 80 5 (8.3) 3 (4.7) 5 (8.6) 7 (11.9) 20 (8.3)
Able to carry on normal activity 90 11 (18.3) 16 (25.0) 9 (15.5) 15 (25.4) 51 (21.2)
Normal 100 44 (73.3) 44 (68.8) 41 (70.7) 35 (59.3) 164 (68.0)
Not done   0 (0.0) 1 (1.56) 1 (1.72) 0 (0.0) 2 (0.8)
Hormonal receptor status, N (%) ER+ 44 (73.3) 47 (73.4) 39 (67.2) 46 (78.0) 176 (73.0)
PR+ 38 (63.3) 43 (67.2) 34 (58.6) 42 (71.2) 157 (65.1)
Previous hormonal therapy, N (%) Yes 44 (73.7) 48 (75.0) 40 (69.0) 46 (78.0) 178 (73.9)
No 16 (26.7) 16 (25.0) 17 (29.3) 13 (22.0) 62 (25.7)
Visceral metastases, N (%) Absence 19 (31.7) 19 (29.7) 16 (27.6) 23 (39.0) 77 (32.0)
Presence 41 (68.3) 45 (70.3) 42 (72.4) 36 (61.0) 164 (68.0
Previous adjuvant/neoadjuvant taxane therapyb, N (%) Yes 21 (35.0) 24 (37.5) 12 (20.7) 19 (32.2) 76 (31.5)
  No 39 (65.0) 40 (62.5) 45 (77.6) 40 (67.8) 164 (68.0)
  1. aOther: 1 Creole; b1 patient in Arm C had no record for previous hormonal therapy and adjuvant/neoadjuvant therapy.
  2. Arm A: docetaxel and gemcitabine with 3-weekly schedule; Arm B: paclitaxel and gemcitabine with 3-weekly schedule; Arm C: docetaxel and gemcitabine with weekly schedule; Arm D: paclitaxel and gemcitabine with weekly schedule.
  3. PR: Partial Response.